Jean-Daniel Lelièvre

Prof. Jean-Daniel Lelièvre

Inserm
+2
orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2017 in The Lancet Infectious Diseases
Verified
Journal Article
Open access
CCCaroline Charlier
Caroline Charlier
ÉPÉlodie Perrodeau
Élodie Perrodeau
Alexandre LeclercqAlexandre Leclercq
Alexandre Leclercq
BCBenoît Cazenave
Benoît Cazenave
BPBenoît Pilmis
Benoît Pilmis
CZChristian Zumbo
Christian Zumbo
Listeriosis is a severe foodborne infection and a notifiable disease in France. We did a nationwide prospective study to characterise its clinical features and prognostic factors. MONALISA was a national prospective observational cohort study. We enrolled eligible cases declared to the National Reference Center for Listeria (all microbiologically proven) between Nov 3, 2009, and July 31, 2013, in the context of mandatory reporting. The outcomes were analysis of clinical features, characterisation of Listeria isolates, and determination of predictors of 3-month mortality or persisting impairment using logistic regression. A hierarchical clustering on principal components was also done for neurological and bacteraemic cases. The study is registered at ClinicalTrials.gov, number NCT01520597. We enrolled 818 cases from 372 centres, including 107 maternal-neonatal infections, 427 cases of bacteraemia, and 252 cases of neurolisteriosis. Only five (5%) of 107 pregnant women had an uneventful outcome. 26 (24%) of 107 mothers experienced fetal loss, but never after 29 weeks of gestation or beyond 2 days of admission to hospital. Neurolisteriosis presented as meningoencephalitis in 212 (84%) of 252 patients; brainstem involvement was only reported in 42 (17%) of 252 patients. 3-month mortality was higher for bacteraemia than neurolisteriosis (hazard ratio [HR] 0·54 [95% CI 0·41-0·69], p<0·0001). For both bacteraemia and neurolisteriosis, the strongest mortality predictors were ongoing cancer (odds ratio [OR] 5·19 [95% CI 3·01-8·95], p<0·0001), multi-organ failure (OR 7·98 [4·32-14·72], p<0·0001), aggravation of any pre-existing organ dysfunction (OR 4·35 [2·79-6·81], p<0·0001), and monocytopenia (OR 3·70 [1·82-7·49], p=0·0003). Neurolisteriosis mortality was higher in blood-culture positive patients (OR 3·67 [1·60-8·40], p=0·002) or those receiving adjunctive dexamethasone (OR 4·58 [1·50-13·98], p=0·008). The severity of listeriosis is higher than reported elsewhere. We found evidence of a significantly reduced survival in patients with neurolisteriosis treated with adjunctive dexamethasone, and also determined the time window for fetal losses. MONALISA provides important new data to improve management and predict outcome in listeriosis. Programme Hospitalier Recherche Clinique, Institut Pasteur, Inserm, French Public Health Agency.

1 December 2013 in Immunity
Verified
Journal Article
Closed access
XLXavier Lahaye
Xavier Lahaye
TSTakeshi Satoh
Takeshi Satoh
MGMatteo Gentili
Matteo Gentili
SCSilvia Cerboni
Silvia Cerboni
CCCécile Conrad
Cécile Conrad
NMNicolas Manel
Nicolas Manel

15 March 2017 in Nature
Verified
Journal Article
Closed access
BDBenjamin Descours
Benjamin Descours
GPGaël Petitjean
Gaël Petitjean
JLJosé-Luis López-Zaragoza
José-Luis López-Zaragoza
TBTimothée Bruel
Timothée Bruel
RRRaoul Raffel
Raoul Raffel
MBMonsef Benkirane
Monsef Benkirane

16 March 2009 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
YLYves Levy
Yves Levy
CLChristine Lacabaratz
Christine Lacabaratz
LWLaurence Weiss
Laurence Weiss
JVJean-Paul Viard
Jean-Paul Viard
CGCecile Goujard
Cecile Goujard
JDJean-François Delfraissy
Jean-François Delfraissy
HIV infection results in CD4+ T cell deficiency, but efficient combination antiretroviral therapy (c-ART) restores T cells and decreases morbidity and mortality. However, immune restoration by c-ART remains variable, and prolonged T cell deficiency remains in a substantial proportion of patients. In a prospective open-label phase I/IIa trial, we evaluated the safety and efficacy of administration of the T cell regulator IL-7. The trial included 13 c-ART–treated HIV-infected patients whose CD4+ cell counts were between 100 and 400 cells/μl and plasma HIV RNA levels were less than 50 copies/ml. Patients received a total of 8 subcutaneous injections of 2 different doses of recombinant human IL-7 (rhIL-7; 3 or 10 μg/kg) 3 times per week over a 16-day period. rhIL-7 was well tolerated and induced a sustained increase of naive and central memory CD4+ and CD8+ T cells. In the highest dose group, 4 patients experienced transient increases in viral replication. However, functional assays showed that the expanded T cells responded to HIV antigen by producing IFN-γ and/or IL-2. In conclusion, in lymphopenic HIV-infected patients, rhIL-7 therapy induced substantial functional and quantitative changes in T cells for 48 weeks. Therefore, patients may benefit from intermittent therapy with IL-7 in combination with c-ART.

1 May 2012 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
YLY. Lévy
Y. Lévy
ISI. Sereti
I. Sereti
GTG. Tambussi
G. Tambussi
JRJ. P. Routy
J. P. Routy
Jean-Daniel LelièvreJean-Daniel Lelièvre
Jean-Daniel Lelièvre
MLM. M. Lederman
M. M. Lederman
Background. The immune deficiency of human immunodeficiency virus (HIV) infection is not fully corrected with ARV therapy. Interleukin-7 (IL-7) can boost CD4 T-cell counts, but optimal dosing and mechanisms of cellular increases need to be defined. Methods. We performed a randomized placebo-controlled dose escalation (10, 20 and 30 µg/kg) trial of 3 weekly doses of recombinant human IL-7 (rhIL-7) in ARV-treated HIV-infected persons with CD4 T-cell counts between 101 and 400 cells/µL and plasma HIV levels <50 copies/mL. Toxicity, activity and the impact of rhIL-7 on immune reconstitution were monitored. Results. Doses of rhIL-7 up to 20 µg/kg were well tolerated. CD4 increases of predominantly naive and central memory T cells were brisk (averaging 323 cells/µL at 12 weeks) and durable (up to 1 year). Increased cell cycling and transient increased bcl-2 expression were noted. Expanded cells did not have the characteristics of regulatory or activated T cells. Transient low-level HIV viremia was seen in 6 of 26 treated patients; modest increases in total levels of intracellular HIV DNA were proportional to CD4 T-cell expansions. IL-7 seemed to increase thymic output and tended to improve the T-cell receptor (TCR) repertoire in persons with low TCR diversity. Conclusions. Three weekly doses of rhIL-7 at 20 µg/kg are well tolerated and lead to a dose-dependent CD4 T-cell increase and the broadening of TCR diversity in some subjects. These data suggest that this rhIL-7 dose could be advanced in future rhIL-7 clinical studies. Clinical Trials Registration NCT0047732.

1 November 2012 in Molecular Cell
Verified
Journal Article
Closed access
AYAhmad Yatim
Ahmad Yatim
CBClarisse Benne
Clarisse Benne
BSBijan Sobhian
Bijan Sobhian
SLSabine Laurent-Chabalier
Sabine Laurent-Chabalier
ODOlivier Deas
Olivier Deas
MBMonsef Benkirane
Monsef Benkirane